ReviewAntibiotics (Basel, Switzerland)2022
Nanomaterials-Based Combinatorial Therapy as a Strategy to Combat Antibiotic Resistance.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-ResistantPharmaceutics · 2026Review
- Hydrogel-Based Platforms for Wound Care: Integrated Strategies for Antimicrobial Delivery and Biofilm Management.Gels (Basel, Switzerland) · 2026Review
- Antimicrobial nanomaterials at the nanoscale: design principles, mechanisms, and global challenges.Nanoscale advances · 2026Review
- Multiple virulence attenuating strategies against Pseudomonas aeruginosa: Natural, synthetic, and synergistic approaches.World journal of microbiology & biotechnology · 2026Review
- Environmental Antimicrobial Resistance: Key Drivers, Hotspots, Innovative Strategies, and Challenges in the Fight Against Superbugs.MicrobiologyOpen · 2025Review
- Combating Healthcare-Associated Infections in Modern Hospitals: Nanotechnology-Based Approaches in the Era of Antimicrobial Resistance.Nanomaterials (Basel, Switzerland) · 2025Review
- Bactericidal, Virucidal, and Biocompatible Properties of 3D Printed Materials Enhanced with Copper and Zinc Nanoparticles.Global challenges (Hoboken, NJ) · 2025Article
- Unlocking the synergistic potential of green metallic nanoparticles and antibiotics for antibacterial and wound healing activities.iScience · 2025Review
- Article
- Advancements in Antibacterial Therapy: Feature Papers.Microorganisms · 2025Review
- Nanomaterial-Based Strategies to Combat Antibiotic Resistance: Mechanisms and Applications.Antibiotics (Basel, Switzerland) · 2025Review
- Advances in hybridized nanoarchitectures for improved oro-dental health.Journal of nanobiotechnology · 2024Review
- Enhanced Antibacterial Efficacy of Bioceramic Implants Functionalized with Ciprofloxacin: An In Silico and In Vitro Study.Pharmaceutics · 2024Article
- Advancements in the Synthesis and Functionalization of Zinc Oxide-Based Nanomaterials for Enhanced Oral Cancer Therapy.Molecules (Basel, Switzerland) · 2024Review
- The Biofilm Inhibition Properties of Glucosamine Gold Nanoparticles in Combination with Meropenem againstMaterials (Basel, Switzerland) · 2024Article
- Current Overview of Metal Nanoparticles' Synthesis, Characterization, and Biomedical Applications, with a Focus on Silver and Gold Nanoparticles.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Shaping Silver Nanoparticles' Size through the Carrier Composition: Synthesis and Antimicrobial Activity.Nanomaterials (Basel, Switzerland) · 2023Article
- Recent Advances in the Development of Lipid-, Metal-, Carbon-, and Polymer-Based Nanomaterials for Antibacterial Applications.Nanomaterials (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Since the discovery of antibiotics, humanity has been able to cope with the battle against bacterial infections. However, the inappropriate use of antibiotics, the lack of innovation in therapeutic agents, and other factors have allowed the emergence of new bacterial strains resistant to multiple antibiotic treatments, causing a crisis in the health sector. Furthermore, the World Health Organization has listed a series of pathogens (ESKAPE group) that have acquired new and varied resistance to different antibiotics families. Therefore, the scientific community has prioritized designing and developing novel treatments to combat these ESKAPE pathogens and other emergent multidrug-resistant bacteria. One of the solutions is the use of combinatorial therapies. Combinatorial therapies seek to enhance the effects of individual treatments at lower doses, bringing the advantage of being, in most cases, much less harmful to patients. Among the new developments in combinatorial therapies, nanomaterials have gained significant interest. Some of the most promising nanotherapeutics include polymers, inorganic nanoparticles, and antimicrobial peptides due to their bactericidal and nanocarrier properties. Therefore, this review focuses on discussing the state-of-the-art of the most significant advances and concludes with a perspective on the future developments of nanotherapeutic combinatorial treatments that target bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.